Latest Conference Articles

Cost-effectiveness thresholds can do more than just guide determinations on whether drugs have value, explained Patricia Danzon, PhD, professor at the Wharton School at the University of Pennsylvania. Using these thresholds as a requirement for reimbursement provides an incentive for research and development focused on producing new drugs that will be considered effective enough to pay for.

The notion of letting Medicare negotiate drug prices has been around for years, but has recently gained new traction under President Donald Trump. Panelists at the ISPOR 22nd Annual International Meeting, held May 20-24 in Boston, Massachusetts, discussed the complexities of allowing Medicare to negotiate prices and whether or not it would produce meaningful savings.

Measure developers have a number of challenges to consider when developing a new measure and getting it implemented, explained Matthew Pickering, PharmD, RPh, associate director of research and quality strategies at the Pharmacy Quality Alliance (PQA).

Thresholds can be useful to focus the conversation around the value of treatments in healthcare even if stakeholders have different views on what thresholds should be, explained Steve Pearson, MD, MSc, president of the Institute for Clinical and Economic Review.

Is it possible to leverage social networks to influence response to treatment among an untreated population? During the second plenary at the ISPOR 22nd Annual International Meeting, held May 20-24 in Boston, Massachusetts, Nicholas Christakis, MD, PhD, of Yale University, described his research into social network interventions.

A tailored approach to value assessment will help drive innovation and impact patient outcomes and access to care, said Ilene Hollin, PhD, MPH, of the National Pharmaceutical Council.

Of the payers who have an outcomes-based contract in place, only 9% view them as being very successful, while 50% say they are somewhat successful. Panelists agreed that flexibility is necessary for these contracts to succeed.

Every 5 years, the Children's Health Insurance Program (CHIP) has to be reauthorized. This year the program has to be reauthorized by September, and that normally would have happened by now, except the issue has flown under the radar with the other big healthcare issues dominating Congress' attention, explained David. M. Cutler, PhD, of Harvard University.

Stakeholders’ perspectives can vary, and their different preferences matter when it comes to value assessment, but only if the right questions are being asked.

While there is a lot of uncertainty about what the final Senate healthcare reform bill will look like, Gail Wilensky, PhD, of Project HOPE, expects the bill will ultimately be to the left of the House bill in order to get the moderates on board.

Healthcare is a complicated issue with few, if any, easy fixes. The important thing is that the country continues to move forward, according to panelists during the first plenary at the ISPOR 22nd Annual International Meeting, held May 20-24 in Boston, Massachusetts.

About 40% of new specialty drugs in 2017 are expected to be for orphan drug indications, which is keeping with the trend; however, an upcoming investigation into potential abuses of the Orphan Drug Act could have an unknown impact on development and prices, said Aimee Tharaldson, PharmD, senior clinical consultant for emerging therapeutics at Express Scripts.

With the high cost of new drugs to cure hepatitis C, ensuring that real-world outcomes are consistent with those seen in clinical trials is important, explained Gail Bridges, PharmD, of Accredo Health. She explained that Accredo ensured patients adhered to hepatitis C drugs in order to get the best outcomes through a disease- and drug-specific education program.

Matthew Gubens, MD, MS, assistant clinical professor of thoracic oncology at the University of California, San Francisco, discussed the areas of lung immuno-oncology research where he anticipates significant advances will be made in coming years.

Findings from real-world studies will help clinicians and other health stakeholders better understand the use of Toujeo compared with Lantus, particularly regarding treatment dosage patterns, for patients with type 2 diabetes, according to Liz Zhou, MD, director of evidence-based medicine at Sanofi Medical Affairs.

According to Richard J. Willke, PhD, chief science officer of ISPOR, real-world data has some unique advantages over randomized clinical trial findings, especially for health plans looking to make coverage decisions.

Although it may be costly to negotiate and implement risk-based arrangements, these agreements are a valuable tool for testing outcomes in the real world among complex patients, explained Lou Garrison, PhD, professor emeritus in the Department of Pharmacy, University of Washington.

The REACH trial of an eCounseling program to reduce hypertension was effective because it encouraged patients to see themselves as an active member of the team, according to lead study author Rob Nolan, PhD, CPsych, director of Cardiac eHealth at the Peter Munk Cardiac Centre and clinical psychologist and scientist at the Toronto General Research Institute.

When developing interventions to improve population health, particularly among minority groups, research must take a culturally sensitive approach that is targeted to the specific needs of that population, according to Moon S. Chen Jr, PhD, MPH, professor of hematology and oncology at UC Davis Comprehensive Cancer Center and principal investigator of The National Center for Reducing Asian American Cancer Health Disparities. He also emphasized the importance of clinicians’ role in population health.

As healthcare moves more toward a system of value-based care, ethical committees are becoming more important to ensuring an institution's ethical values are evident in the way it provides care to patients, explained Jacqueline Glover, PhD, professor in the Department of Pediatrics and the Center for Bioethics and Humanities at the University of Colorado Denver.

Findings from 2 Phase III trials of plecanatide were presented at Digestive Disease Week, held May 6-9 in Chicago, Illinois.

It remains unclear why insurers approve some patients for PCSK9 inhibitors while denying others with similar clinical characteristics, according to Seth J. Baum, MD, FACC, FACPM, FAHA, FNLA, FASPC, president of the American Society for Preventive Cardiology, who presented an abstract on the subject at the American College of Cardiology 66th Scientific Session.

At Digestive Disease Week 2017, held May 6-9 in Chicago, Illinois, researchers presented their work to develop a capsule scope that can harness the power of magnetics and robotics to autonomously explore the colon.

The future of healthcare should be taking care of patients in the context of their lives, whether that is addressing their hunger, transportation needs, or loneliness, explained Sachin H. Jain, MD, MBA, president and CEO of CareMore.

A lack of diversity in study groups is a common problem in clinical trials, including those researching gastrointestinal (GI) diseases. Speakers at Digestive Disease Week 2017, held May 6-9 in Chicago, discussed the roots of this issue and what they have found to address it.

Hospitalized patients who are obese are more likely to be readmitted and have longer and costlier inpatient stays, but tend to have lower mortality rates, according to new research presented at Digestive Disease Week 2017, held May 6-9 in Chicago, Illinois.

As the number of mobile health applications continues to skyrocket, a group of researchers set out to determine whether a smartphone app could prevent readmissions for patients released from the hospital after gastrointestinal (GI) surgery. The findings from the pilot study of their mHEALS app were presented at Digestive Disease Week 2017, which took place May 6-9 in Chicago.

At a session during Digestive Disease Week 2017, held May 6-9 in Chicago, speakers highlighted some new approaches to managing obesity that are now approved by the FDA.

At Digestive Disease Week 2017, held May 6-9 in Chicago, researchers presented their findings from a trial of a text messaging intervention to encourage weight loss and liver health in patients with non-alcoholic fatty liver disease (NAFLD).

As CMS developed the Medicare Access and CHIP Reauthorization Act (MACRA) over the past few years, it was responsive to the needs and concerns of clinicians, according to William Borden, MD, FACC, FAHA, associate professor of medicine and director of healthcare delivery transformation at the George Washington University. Still, Borden says there are ways the requirements could be simplified, which would benefit both physicians and patients.